Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Arch Biopartners Engages Cantox to Devise Drug Development Plan for GH501a
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Arch Biopartners Inc has announced that it has engaged Intertek Cantox to devise the drug development plan for the Company's lead compound, GH501a.
The Company recently identified GH501a as a potential treatment for non-small cell lung cancer and pancreatic cancer.
The drug development plan is expected to be complete by the end of 2011 and will focus in detail on the steps that need to be completed by the Company in order to submit an Investigational New Drug ("IND") application and pursue subsequent human trials.
